Want to join the conversation?
$ALXN received FDA approval for bone disease therapy. Strensiq, which will treat perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP), will be available commercially by Oct. 27. This was based on data from 4 clinical trials and supporting extension trials. The most commonly reported adverse events observed were injection site reactions.
$PYPL jumps 6% in after hours on strong results. I am bullish on this stock.
$TSCO stock remained active in the after hours trading and rose more than 2% after the retailer posted better than expected 1Q17 results.
Instagram has reached 700 million monthly active users. Looks like it will hit 1 billion soon. That would make it $FB’s fourth billion-user platform.